In recent years, the enzyme prolyl oligopeptidase (POP, EC 3.4.21.26) has gained importance as a target for the treatment of schizophrenia (SZ), bipolar affective disorder (BD) and cognitive disturbances, such as those present in Alzheimer’s disease (AD). The gene discussed is PREP; the disease is Alzheimer disease.